Promise Bio, a Tel Aviv, Israel-based startup advancing immune-mediated disease treatment with precision medicine solutions, raised $8.3M in Seed funding.
The round was led by Awz Ventures, with participation from AION Lab’s venture seeding track from AstraZeneca and Pfizer along a grant from the Israel Innovation Authority.
The company intends to use the funds to accelerate the development of its computational platform, which uses epiproteomics and artificial intelligence to predict patient treatment responses and support drug research and development.
Led by CEO Ronel Veksler and CTO Assaf Kacen, Promise Bio is a precision medicine company focused on transforming the management of immune-mediated diseases through epiproteomics and artificial intelligence. Built on research from the Weizmann Institute of Science, it analyzes proteins and their post-translational modifications (PTMs) with exceptional precision. This proprietary technology allows for large-scale PTM profiling, helping researchers uncover disease mechanisms, tailor therapies, and discover new drug targets.
FinSMEs
16/12/2024